Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Access expired on Thursday, January 31, 2019

This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.

Already Have An Account? Log in Now

Register Now
featured
Published in Advanced Prostate Cancer and
2 other channels

Journal Scan / Research · January 15, 2019

Radiotherapy and Short- vs Intermediate-Term Androgen Suppression ± Zoledronic Acid in Locally Advanced Disease

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Fred Saad MD, FRCS

The Lancet Oncology
Short-Term Androgen Suppression and Radiotherapy Versus Intermediate-Term Androgen Suppression and Radiotherapy, With or Without Zoledronic Acid, in Men With Locally Advanced Prostate Cancer (TROG 03.04 RADAR): 10-Year Results From a Randomised, Phase 3, Factorial Trial
Lancet Oncol 2018 Dec 19;[EPub Ahead of Print], JW Denham, D Joseph, DS Lamb, NA Spry, G Duchesne, J Matthews, C Atkinson, KH Tai, D Christie, L Kenny, S Turner, NK Gogna, T Diamond, B Delahunt, C Oldmeadow, J Attia, A Steigler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated